140 related articles for article (PubMed ID: 25854459)
1. [Efficacy of continuous low-dose cyclophosphamide and prednisone regimen in refractory multiple myeloma patients with severe heart failure].
Zhou F; Wei W; Ling C; Guo L; Shi H; Li L; Chen X; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2015 Mar; 36(3):186-90. PubMed ID: 25854459
[TBL] [Abstract][Full Text] [Related]
2. Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure.
Zhou F; Ling C; Guo L; Wei W; Li L; Shi H; Hou J
Leuk Lymphoma; 2014 Oct; 55(10):2271-6. PubMed ID: 24467219
[TBL] [Abstract][Full Text] [Related]
3. [Anti-angiogenesis effect of metronomic chemotherapy in multiple myeloma patients].
Guo LP; Zhou F; Wei W; Zhang YZ; Shi HT; Lin CH; Li L; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):457-60. PubMed ID: 22967380
[TBL] [Abstract][Full Text] [Related]
4. Continuous administration of low-dose cyclophosphamide and prednisone as a salvage treatment for multiple myeloma.
Zhou F; Guo L; Shi H; Lin C; Hou J
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):51-5. PubMed ID: 20223729
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
6. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
7. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.
Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; Anglin P; Chen C; Kukreti V; Mikhael JR; Trudel S
Br J Haematol; 2015 Jan; 168(1):46-54. PubMed ID: 25146584
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy Comparison of Low dose Thalidomide Combined with Modified VCMP and VAD regimens for Treatment of Aged MM Patients].
Wang W; Liu HB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):765-8. PubMed ID: 27342506
[TBL] [Abstract][Full Text] [Related]
9. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
[TBL] [Abstract][Full Text] [Related]
10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
11. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
12. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.
Bladé J; San Miguel JF; Fontanillas M; Esteve J; Maldonado J; Alcalá A; Brunet S; García-Conde J; Besalduch J; Moro MJ; Fernández-Calvo J; Conde E; Font L; Gardella S; Carnero M; Carbonell F; Martí JM; Hernández-Martín J; Ortega F; Besses C; Ribera JM; Trujillo J; Escudero ML; Rozman C; Estapé J; Montserrat E
Hematol J; 2001; 2(4):272-8. PubMed ID: 11920260
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of CTD and PCD regimens in treatment of patients with newly diagnosed multiple myeloma].
Gu Y; Yuan YH; Shi QL; Qu XY; Xu J; Guo R; Xu JD; Li JY; Chen LJ
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):279-284. PubMed ID: 28468087
[No Abstract] [Full Text] [Related]
14. Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications.
Shi H; Wei W; Peng R; Chen H; Zhou N; Wu L; Yu W; Zhao W; Hou J; Zhou F
Front Oncol; 2023; 13():1185991. PubMed ID: 37284198
[TBL] [Abstract][Full Text] [Related]
15. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
Zervas K; Pouli A; Gregoraki B; Anagnostopoulos N; Dimopoulos MA; Bourantas K; Tzilianos M; Barbarousi D; Venetis E; Vyniou N; Maniatis A
Eur J Haematol; 2001 Jan; 66(1):18-23. PubMed ID: 11168503
[TBL] [Abstract][Full Text] [Related]
16. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
[TBL] [Abstract][Full Text] [Related]
18. Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma.
de Weerdt O; van de Donk NW; Veth G; Bloem AC; Hagenbeek A; Lokhorst HM
Neth J Med; 2001 Aug; 59(2):50-6. PubMed ID: 11476912
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma.
Reece DE; Trieu Y; Masih-Khan E; Atenafu EG; Chen C; Prica A; Tiedemann R; Trudel S; Kukreti V
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):387-94. PubMed ID: 27349765
[TBL] [Abstract][Full Text] [Related]
20. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.
Suvannasankha A; Fausel C; Juliar BE; Yiannoutsos CT; Fisher WB; Ansari RH; Wood LL; Smith GG; Cripe LD; Abonour R
Oncologist; 2007 Jan; 12(1):99-106. PubMed ID: 17227904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
